BiotechTube

5% Minoxidil + 2% Minoxidil

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alopecia

Conditions

Alopecia

Trial Timeline

Jun 1, 2010 → Feb 1, 2012

NCT ID
NCT01145625

About 5% Minoxidil + 2% Minoxidil

5% Minoxidil + 2% Minoxidil is a phase 3 stage product being developed by Johnson & Johnson for Alopecia. The current trial status is completed. This product is registered under clinical trial identifier NCT01145625. Target conditions include Alopecia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01145625Phase 3Completed

Competing Products

20 competing products in Alopecia

See all competitors
ProductCompanyStageHype Score
BaricitinibEli LillyPhase 2
52
CTP-543Sun PharmaceuticalPhase 2/3
65
CTP-543Sun PharmaceuticalPhase 3
77
Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2/3
65
Baricitinib 4 MG Oral TabletEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
minoxidilJohnson & JohnsonPhase 3
77
Minoxidil + vehicle of 5% Minoxidil topical foamJohnson & JohnsonPhase 2
52
5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3
77
Upadacitinib + Upadacitinib PlaceboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 3
77
Secukinumab + PlaceboNovartisPhase 2
52
DaxdilimabAmgenPhase 2
51
RitlecitinibPfizerPre-clinical
22
LITFULOPfizerPre-clinical
22
RitlecitinibPfizerPre-clinical
22
Ritlecitinib higher dose + Ritlecitinib lower dose + PlaceboPfizerPhase 3
76
RitlecitinibPfizerPre-clinical
22

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85